Alphaeon has signed an agreement to acquire US-based commercial stage medical device firm Lensar, for around $59m.
Established in 2004 and based in Orlando of Florida, Lensar developed Femtosecond laser technology for cataract treatment.
The technology was developed to enable automation of several critical surgical procedure planning and delivering elements.
Through its wholly-owned subsidiary, Lensar produces Femtosecond lasers systems (FLS), which were designed for patients seeking a premium vision outcome following the removal of their crystalline lens.
Alphaeon CEO Robert Grant said: "Lensar has advanced the self-pay category of precision refractive surgery both for ophthalmologists as well as their patients.
"The addition of Lensar to our lifestyle product portfolio will provide ophthalmologists with another alternative to expand their offering to patients."
Lensar CEO Nick Curtis said: "The opportunity to partner with Alphaeon furthers Lensar’s commitment to provide ophthalmologists everywhere with the latest developments in premium vision surgery."
The deal will allow Alphaeon to expand its ophthalmology business, providing advanced technology to around 2,000 board-certified ophthalmologists across the globe.
Subject to certain closing conditions, the deal is expected to complete by the end of this year.
In December 2014, Alphaeon acquired Canada-based Clarion Medical Technologies, for around $55m.
Established in 1989, Clarion supplies medical and aesthetic equipment and consumables for hospitals and private practices in Canada.